Abstracts - faqs.org

Abstracts

Business, general

Search abstracts:
Abstracts » Business, general

Drug industry

Article Abstract:

Investors must be cautious in selecting pharmaceutical companies for investment purposes throughout 1996 and can no longer use the guidelines that proved so successful in 1995. Although earnings for some pharmaceutical companies will show double digit increases and acquisitions and mergers should continue, these factors will not necessarily guarantee good stock performance, as demonstrated by results in the 1st qtr 1996 when earnings acceleratwd and stock prices dropped.

Author: Clark, Charles, Butler, Jeremy J., Markey, Keith A., Ferguson, Keith E., Rho, George I.H., Ramgopal, Lalishwar, Butler, Jeremy J,
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1996
Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Drugs, Genetic Engineering, Pharmaceutical industry, Eli Lilly and Co., Pfizer Inc., Pharmacia and Upjohn Inc., Glaxo Wellcome PLC, Warner-Lambert Co., SmithKline Beecham Group PLC, Bristol-Myers Squibb Co., ALZA Corp., Chiron Corp., Forest Laboratories Inc., Genzyme Corp., IVAX Corp., Mylan Laboratories Inc., Perrigo Co., Schering-Plough Corp., AZA, AHP, BMY, CHIR, CYGN, FRX, GENZ, ICN, IVX, LLY, MLY, PRGO, PFE, SGP, WLA, Genetics Institute Inc., GENI, Valeant Pharmaceuticals International, Wyeth, Merck & Company Inc., Rhone-Poulenc Rorer Inc., Cygnus Therapeutic Systems, Roberts Pharmaceutical Corp., RPCX, R.P. Scherer Corp., RPR, Gensia Pharmaceuticals Inc., GNSA, SHR

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Biotechnology industry

Article Abstract:

Share prices for biotechnology companies have increased in 2001 and are well-ranked for performance in the coming 12 months. A shift, also, from drug development to genome research is taking place within the industry. Several of these stocks have appreciation potential in spite of the industry's volatile nature.

Author: Feenan, Gerard, Clark, Charles, Markey, Keith A., Ferrara, J. Susan, Chow, Nancy
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2001
United States, Statistical Data Included, Industry Overview, Human Genome Sciences Inc., Millennium Pharmaceuticals Inc., HGSI, MLNM, Myriad Genetics Inc., Invitrogen Corp., IVGN, Enzo Biochem Inc., ENZ, Vertex Pharmaceuticals Inc., VRTX, Neose Technologies Inc., Regeneron Pharmaceuticals Inc., Techne Corp., NTEC, REGN, TECH

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Biotechnology industry

Article Abstract:

Issues are presented concerning the performance of securities in the Biotechnology Industry sector. Statistics detailing the performance of individual companies within the sector are included.

Author: Markey, Keith A.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2001
Stocks & Other Equity Securities

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Evaluation, Biotechnology industry, Biotechnology industries, Biochemistry, Finance, Securities, Genentech Inc., Biogen Inc., Amgen Inc., Immunex Corp., AMGN, BGEN, IMNX, GNE
Similar abstracts:
  • Abstracts: Pharmacy services industry. Drugstore industry
  • Abstracts: Aerospace/defense industry. Aerospace defense industry
  • Abstracts: Steel (general) industry. part 3
  • Abstracts: Insurance (diversified). Insurance (property/casualty)
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.